Home Newsfeeds Guggenheim Downgrades Relmada Therapeutics to Neutral

Guggenheim Downgrades Relmada Therapeutics to Neutral

Guggenheim analyst Yatin Suneja downgrades Relmada Therapeutics (NASDAQ:RLMD) from Buy to Neutral.

byBenzinga Newsdesk

October 14, 2022

1 minute read

Guggenheim analyst Yatin Suneja downgrades Relmada Therapeutics (NASDAQ:RLMD) from Buy to Neutral.

GSK Touts Encouraging Data From Mid-Stage Tuberculosis Program In Drug-Susceptible Patients

By Vandana Singh

November 14, 1:34 PM

GSK plc (NYSE:GSK) announced positive results from a Phase 2a study demonstrating that GSK3036656, an investigational antitubercular agent, was well tolerated…

GSK

Skyline Champion Q3 EPS $1.44 Beats $0.92 Estimate, Sales $582.32M Beat $533.13M Estimate

By Happy Mohamed

February 6, 5:31 PM

Skyline Champion (NYSE:SKY) reported quarterly earnings of $1.44 per share which beat the analyst consensus estimate of $0.92 by 56.52 percent. This is a 22.03 percent increase over earnings of $1.18 per share from the

SKY

Cowen & Co. Downgrades Sumo Logic to Market Perform

By Benzinga Newsdesk

February 15, 5:58 AM

Cowen & Co. analyst Derrick Wood downgrades Sumo Logic (NASDAQ:SUMO) from Outperform to Market Perform.

SUMO

News

Why Fisker Stock Is Trading Lower Following Tesla News

By Henry Khederian

January 13, 4:31 PM

Fisker Inc (NYSE: FSR) shares are trading lower by 8.70% to $7.35 going into the close of Friday's session. Shares of EV companies are trading lower during Friday's session after Tesla cut prices in the US and Europe. Lower Tesla prices could raise competition for other EV makers.

FSR

Guggenheim Downgrades Relmada Therapeutics to Neutral

Related Posts

GSK Touts Encouraging Data From Mid-Stage Tuberculosis Program In Drug-Susceptible Patients

Skyline Champion Q3 EPS $1.44 Beats $0.92 Estimate, Sales $582.32M Beat $533.13M Estimate

Cowen & Co. Downgrades Sumo Logic to Market Perform

Why Fisker Stock Is Trading Lower Following Tesla News